|
Mar 19
|
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
|
|
Mar 18
|
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
|
|
Feb 21
|
Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
|
|
Jan 11
|
Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium
|
|
Jan 9
|
2024 Marks a New Era Of Pharmaceutical Innovation
|
|
Jan 9
|
Mainz Biomed Provides Year-End Corporate Review 2023
|
|
Dec 29
|
2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer
|
|
Dec 19
|
Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees
|
|
Dec 12
|
Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland
|
|
Dec 5
|
While Pfizer Faced A Setback, Altimmune, Roche And Mainz Biomed Advanced in The Battle Against Obesity And Colorectal Cancer
|
|
Dec 5
|
Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers
|
|
Nov 29
|
Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast
|
|
Aug 29
|
Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference
|
|
Jun 29
|
Mainz Biomed Secures up to $50M in New Funding
|
|
Apr 27
|
Mainz Biomed to Commence Quarterly Reporting and Present at Equity Forum Spring Conference 2023 in Frankfurt, Germany
|
|
Apr 26
|
Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert® Commercialization in Spain and Portugal
|